Dr. Al Guillem is a veteran of the pharmaceutical industry with nearly 40 years of leadership experience in bringing new therapies to the market and readying pharmaceutical manufacturing facilities for commercial production at both well-established and startup companies. Al brings a deep knowledge and insight into pharmaceutical manufacturing across many dosage forms and manufacturing operations. Previous experiences and successes include:
- Co-founder, President, & CEO at ZS Pharma, a startup company developing a product for hyperkalemia or high levels of potassium in the blood. ZS Pharma was acquired by Astra Zeneca in 2015 for $2.7 billion.
- Adams Respiratory Therapeutics, where he, along with other team members, brought the Mucinex product line to the market. The company later was acquired by Reckitt Benckiser for $2.3 billion in 2007.
- Senior positions at Genzyme/Bone Care, Wyeth, Boehringer Ingelheim, and Medeva Americas.
- Co-founder, President, & CEO at ZS Pharma, a startup company developing a product for hyperkalemia or high levels of potassium in the blood. ZS Pharma was acquired by Astra Zeneca in 2015 for $2.7 billion.
- Adams Respiratory Therapeutics, where he, along with other team members, brought the Mucinex product line to the market. The company later was acquired by Reckitt Benckiser for $2.3 billion in 2007.
- Senior positions at Genzyme/Bone Care, Wyeth, Boehringer Ingelheim, and Medeva Americas.
Speaking In
[Available On-Demand]
OncoNano has pioneered an ultra pH-sensitive, polymeric micelle platform technology to selectively…
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
